The "Intermediate AMD - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of Intermediate AMD, historical and forecasted ...

Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

Several risk tools can accurately predict individual baseline risks of adverse events in people with chronic kidney disease. Here, the authors examine methods of assessing risk and discuss risk ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

From her Oscar-winning turn as Queen Elizabeth I in Shakespeare in Love to her famously gender-swapped role as "M" in the ...

Fellow-KI researchers Anders Kvanta and Fredrik Lanner have been awarded a grant of SEK 10 million from the Promobilia ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

It comes in two forms: wet and dry. Generally, medications can help with age-related macular degeneration, or AMD. While they don ... long enough to experience severe side effects.

The Macular Society has described the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision to reject a treatment for late-stage dry AMD as “undoubtedly disappointing news.” ...